申请人:Amberg Wilhelm
公开号:US20100041698A1
公开(公告)日:2010-02-18
The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.
该发明涉及一般式(I)的化合物,其相应的对映体、异构体和/或互变异构体形式,以及其药学上可接受的盐和所述化合物的前药。该发明还涉及将所述化合物用作5-HT5受体的结合伙伴,用于治疗受5-HT5受体活性调节的疾病,特别是用于治疗神经退行性和神经精神障碍以及相关的症状和功能障碍。